ClinicalTrials.gg

Program

Pn-MAPS30plus

A development code.

Its studies are mostly in Pneumonia, Bacterial, led by GlaxoSmithKline.

Furthest: phase 1, since Aug 4, 20254 company-led studies, 3 open or runningNext primary completion: Nov 19, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline43 open or runningphase 1since Aug 4, 2025Aug 4, 2025Nov 19, 2026phase 1 · NCT07428759

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 4, 2025First study: phase 1 study in Pneumonia, BacterialFirst studyNCT07105722 · 127 enrolled · Australia
  2. Feb 6, 20263 phase 1 studies in Pneumonia, BacterialNCT07406347, NCT07406334, NCT07428759

Ahead

  1. Nov 19, 2026Primary completion: phase 1 study in Pneumonia, BacterialNCT07428759
  2. Feb 22, 2027Primary completion: phase 1 study in Pneumonia, BacterialNCT07406334
  3. Oct 18, 2028Primary completion: phase 1 study in Pneumonia, BacterialNCT07406347

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07428759Pneumonia, Bacterial · Australia1Active, not recruitingNov 19, 2026122
NCT07406347Pneumonia, Bacterial1Not yet recruitingOct 18, 202860
NCT07406334Pneumonia, Bacterial · South Africa1Active, not recruitingFeb 22, 202746
NCT07105722Pneumonia, Bacterial · Australia1CompletedMay 6, 2026127

How it is read

Names in the registry

  • “Pn-MAPS30plus”, 4 entries

Codes read as this program: PNMAPS30PLUS.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
Pn-MAPS30plus (GlaxoSmithKline): development program | ClinicalTrials.gg